Use of Micafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 3,764 Clinical Isolates of Candida by Use of CLSI Methods and Interpretive Criteria
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Use of Micafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 3,764 Clinical Isolates of Candida by Use of CLSI Methods and Interpretive Criteria
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL MICROBIOLOGY
Volume 52, Issue 1, Pages 108-114
Publisher
American Society for Microbiology
Online
2013-10-24
DOI
10.1128/jcm.02481-13
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Caspofungin MICs Correlate with Treatment Outcomes among Patients with Candida glabrata Invasive Candidiasis and Prior Echinocandin Exposure
- (2013) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations
- (2013) Barbara D. Alexander et al. CLINICAL INFECTIOUS DISEASES
- Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance
- (2013) M. A. Pfaller et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Caspofungin Etest Susceptibility Testing of Candida Species: Risk of Misclassification of Susceptible Isolates of C. glabrata and C. krusei when Adopting the Revised CLSI Caspofungin Breakpoints
- (2012) Maiken Cavling Arendrup et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination viaIn VivoPharmacodynamic Evaluation against Candida glabrata with and withoutfksMutations
- (2012) Alexander Lepak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Recurrent Episodes of Candidemia Due to Candida glabrata with a Mutation in Hot Spot 1 of theFKS2Gene Developed after Prolonged Therapy with Caspofungin
- (2012) María Teresa Durán-Valle et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Stepwise Development of a Homozygous S80P Substitution in Fks1p, Conferring Echinocandin Resistance in Candida tropicalis
- (2012) Rasmus Hare Jensen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- DifferentialIn VivoActivities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and withoutFKSResistance Mutations
- (2012) Maiken Cavling Arendrup et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)
- (2012) A.J. Ullmann et al. CLINICAL MICROBIOLOGY AND INFECTION
- ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients
- (2012) O.A. Cornely et al. CLINICAL MICROBIOLOGY AND INFECTION
- EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)*
- (2012) Maiken C. Arendrup et al. CLINICAL MICROBIOLOGY AND INFECTION
- Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata
- (2012) M. A. Pfaller et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012
- (2012) M. A. Pfaller et al. JOURNAL OF CLINICAL MICROBIOLOGY
- CRS-MIS inCandida glabrata: sphingolipids modulate echinocandin-Fks interaction
- (2012) Kelley R. Healey et al. MOLECULAR MICROBIOLOGY
- Evaluation of CLSI M44-A2 Disk Diffusion and Associated Breakpoint Testing of Caspofungin and Micafungin Using a Well-Characterized Panel of Wild-Type andfksHot Spot Mutant Candida Isolates
- (2011) Maiken Cavling Arendrup et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Candida glabrataMutants Demonstrating Paradoxical Reduced Caspofungin Susceptibility but Increased Micafungin Susceptibility
- (2011) Kelley R. Healey et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Disseminated Candidiasis Caused by Candida albicans with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin
- (2011) J. L. Slater et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Echinocandin Susceptibility Testing ofCandidaspp. Using EUCAST EDef 7.1 and CLSI M27-A3 Standard Procedures: Analysis of the Influence of Bovine Serum Albumin Supplementation, Storage Time, and Drug Lots
- (2011) Maiken Cavling Arendrup et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata
- (2011) Elisabetta Spreghini et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics of Echinocandins against Candida glabrata: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts
- (2011) Susan J. Howard et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria
- (2011) M.A. Pfaller et al. DRUG RESISTANCE UPDATES
- Development of Echinocandin Resistance in Clavispora lusitaniae during Caspofungin Treatment
- (2011) Marie Desnos-Ollivier et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains
- (2010) M. Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 Patients
- (2010) Olivier Lortholary et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species
- (2010) G. Garcia-Effron et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Breakthrough Invasive Candidiasis in Patients on Micafungin
- (2010) C. D. Pfeiffer et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Echinocandin Susceptibility Testing of Candida Species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest Media
- (2009) M. C. Arendrup et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3- -D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint
- (2009) G. Garcia-Effron et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America
- (2009) Peter G. Pappas et al. CLINICAL INFECTIOUS DISEASES
- Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins andCandidaspp.
- (2009) M. A. Pfaller et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing
- (2008) M. C. Arendrup et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints
- (2008) M. A. Pfaller et al. JOURNAL OF CLINICAL MICROBIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started